Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innovation Pharmaceuticals Inc IPIX

Healthcare Biotechnology
Innovation Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the business of developing or licensing small molecule therapies. The Company’s lead drug candidate, Brilacidin, is in a class of compounds called defensin-mimetics, small compounds that mimic the structure and function of defensins, also known as host defense peptides. The Company’s efforts... see more

Recent & Breaking News (GREY:IPIX)

Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024

GlobeNewswire August 28, 2023

Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases

GlobeNewswire June 21, 2023

Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing

GlobeNewswire June 5, 2023

Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications

GlobeNewswire April 17, 2023

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

GlobeNewswire March 15, 2023

Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission

GlobeNewswire February 23, 2023

Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement

GlobeNewswire January 9, 2023

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis

GlobeNewswire December 13, 2022

Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family

GlobeNewswire November 28, 2022

NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"

GlobeNewswire October 26, 2022

Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin

GlobeNewswire October 4, 2022

New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals' Brilacidin Presented at 2022 Military Health System Research Symposium

Accesswire September 15, 2022

Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform

Accesswire September 13, 2022

Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated Researchers to Evaluate Brilacidin's Treatment Potential Against Monkeypox

Accesswire August 5, 2022

Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical's Brilacidin as a Novel Oral Mucositis Drug Candidate

Accesswire July 22, 2022

Innovation Pharmaceuticals Announces New Antiviral Research on Brilacidin in Bunyaviruses and Alphaviruses to be Presented at the 2022 Military Health System Research Symposium

Accesswire June 28, 2022

Innovation Pharmaceuticals Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing by NIH/NIAID-Sponsored and Rutgers University Researchers

Accesswire June 23, 2022

Innovation Pharmaceuticals Acquires Stake in Squalus Medical, Seeks to Reshape Cancer and Epilepsy Treatments Through a New Image Guided Laser-Based Ablation Technology

Accesswire June 15, 2022

Innovation Pharmaceuticals Announces Publication of Peer-Review Article in the Journal of Medical Virology on Anti-Coronavirus Properties of Brilacidin

Accesswire March 15, 2022

Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases

Accesswire March 7, 2022